Dec. 23, 2015 | Prime Therapeutics
REPORT: Defining parallels
As the Health Insurance Marketplace (HIM) matures into its second year, we’ve discovered a number of interesting parallels — and a few significant differences — in the way public exchange members use medicines and accumulate drug spend.
Aug. 15, 2015 | Prime Therapeutics
REPORT: 2014 prescription drug cost report — Defining dynamics
Prime Therapeutics (Prime) is pleased to announce our 2014 Report on prescription drug costs. This year, our definition of “drug trend” has evolved to reflect the change in net prescription costs. These costs offer the clearest picture of where costs start and how they compare.
June 1, 2015 | Prime Therapeutics
REPORT: Defining variance
Our new white paper, Defining variance, dives deeper into Health Insurance Marketplace data. In it, we explore differences in demographics, use and spend within the five different levels of coverage — identified as “metallic levels.” This analysis revealed more detailed insights and distinctions — and also a few surprises.
April 3, 2015 | Prime Therapeutics
REPORT: 2014 private exchange report — Defining evolution
Last year, Prime served more than 1.4 million public exchange members. Using data from the first full year of the public exchanges, Prime identified drug usage and cost trends. This data gives us perspective on what the future holds for these members. It also gives us insight on what that might mean for Prime in this market.
Feb. 24, 2015 | Prime Therapeutics
REPORT: The economic viability of a U.S. biosimilars industry
A new report sponsored by Prime Therapeutics and authored by health economist Alex Brill suggests the market for biosimilars may not be as robust as many hope it will be. Unlike generic drugs, which significantly impacted the traditional pharmacy market with their cost savings, biosimilars face a number of hurdles.
Aug. 6, 2014 | Prime Therapeutics
REPORT: Enabling better outcomes and lower costs through integration
The report draws on a study sponsored by the Blue Cross and Blue Shield Association (BCBSA) that found positive outcomes and medical cost savings when pharmacy benefits are carved in with the medical. The BCBSA study findings are presented alongside data demonstrating Prime’s notable success in achieving the industry’s lowest net ingredient costs.
June 17, 2014 | Prime Therapeutics
REPORT: Prescription drug cost report — Looking back, moving forward
Prime Therapeutics is pleased to introduce our yearly look back at commercial pharmacy costs and spending trends from the previous year. We’ve renamed our annual trend publication to reflect the inclusion of net ingredient costs. Ingredient cost offers the clearest picture of where costs start and how they compare.